Dexcom (DXCM) Revenue (2010 - 2026)

Dexcom (DXCM) has 17 years of Revenue data on file, last reported at $1.2 billion in Q1 2026.

• Revenue for Q1 2026 came in at $1.2 billion, up 15.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 16.15% YoY), and the FY2025 annual result was $4.7 billion, up 15.6% from the prior year.
• Revenue declined to $1.2 billion in Q1 2026 per DXCM's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Revenue peaked at $1.3 billion in Q4 2025 and troughed at $628.8 million in Q1 2022.
• A 5-year average of $965.8 million and a median of $994.2 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2024: Revenue advanced 26.9% in 2023, then increased 1.97% in 2024.
• A 5-year view of Revenue shows it stood at $815.2 million in 2022, then increased by 26.9% to $1.0 billion in 2023, then climbed by 7.64% to $1.1 billion in 2024, then rose by 13.12% to $1.3 billion in 2025, then dropped by 5.37% to $1.2 billion in 2026.
• Business Quant data shows DXCM's Revenue at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.